Influencia de las comorbilidades en la mortalidad de pacientes con EPOC estables

  1. A. Arnedillo Muñoz 1
  2. J.L. López Campos 2
  3. F. Casas maldonado 3
  4. P. Cordero Montero
  5. I. Alfageme Michavila 4
  1. 1 Unidad de Neumología y Alergia, Hospital Universitario Puerta del Mar
  2. 2 Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla
  3. 3 Servicio de Neumología, Hospital Universitario San Cecilio
  4. 4 Servicio de Neumología, Hospital Universitario Valme
Zugehörigkeit anzeigen +
Zeitschrift:
Revista española de patología torácica

ISSN: 1889-7347

Datum der Publikation: 2017

Ausgabe: 29

Nummer: 2

Seiten: 109-116

Art: Artikel

DIALNET GOOGLE SCHOLAR lock_openOpen Access editor

Andere Publikationen in: Revista española de patología torácica

Zusammenfassung

Objective: to assess the relationship between comorbidities and all-cause mortality in stable chronic obstructive pulmonary disease (COPD) patients, in our geographic area. Methods: Prospective, multicenter, longitudinal study of patients with stable COPD. We recorded demographic characteristics, respiratory functional tests, Charlson comorbidity index and hospital anxiety and depression scale. Patients were followed up for 3 years. In the case of death it was investigated to determine the real cause of death. Results: 138 patients were studied with a mean age of 66.3 ± 10.3 years and mean FEV1 of 51.3 ± 16.9%. The mean Charlson index was 4.66 ± 1.57. 17.2% had depression and 12.7% anxiety. Thirteen (9.5%) patients died, 5 of lung cancer, 5 COPD exacerbation, 1 colon cancer, another for acute myocardial infarction (AMI) and another one for congestive heart failure (CHF). In the multivariate analysis the number of comorbidities (HR 1.926; IC 95%: 1.384 - 2.680) and anxiolytic treatment (HR 4.072; IC 95%: 1.106 - 14.987) showed relationship with mortality. Kaplan-Meier suvival plots showed that patients with 2 o more comorbilities, in addition to COPD, have higher mortality than patients with 1 or no comorbidity (35.52 ± 0.2 vs 33 ± 1.3 months, p = 0,039). Conclusions: The prevalence of comorbidities in patients with stable COPD was high. Mortality in these patients is related to the number of comorbidities and anxiolytic treatment. Mortality was higher in patients with 2 o more comorbidilites.

Bibliographische Referenzen

  • Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for diagnosis, management, and prevention of COPD. Updated 2015. Disponible en: http://www.goldcopd.org/
  • Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of ‘overspill’ of inflammatory mediators from the lungs? Review of the evidence. Thorax 2010; 65: 930-6.
  • Fabbri LM, Luppi F, Beghé B et al. Complex chronic comorbidities of COPD. Eur Respir J 2008; 31 (1): 204-12.
  • Mannino DM, Watt G, Hole D et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 627-43.
  • Cavaille`s A, Brinchault-Rabin G, Dixmier A et al. Comorbidities of COPD. Eur Respir Rev 2013; 22: 454-475.
  • Antonelli-Incalzi R, Fuso L, De Rosa M et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997; 10: 2794-800.
  • Divo M, Cote C, de Torres JP et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. BODE Collaborative Group. Am J Respir Crit Care Med 2012; 186: 155-61.
  • Baty F, Putora PM, Isenring B et al. Comorbidities and burden of COPD: a population based case-control study. PLoS One 2013; 8 (5): e63285.
  • Mannino DM, Thorn D, Swensen A et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32 (4): 962-9.
  • Holguin F, Folch E, Redd SC et al. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest. 2005: 128 (4): 2005-11.
  • Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
  • Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003; 24 (2): 459-67.
  • Almagro P, Calbo E, Ochoa de Echagüen A et al. Mortality after hospitalization for COPD. Chest 2002; 121 (5): 1441-8.
  • Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361–70.
  • Calverley PM, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. TORCH investigators. N Engl J Med 2007; 356 (8): 775-89.
  • Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. UPLIFT Study Investigators. N Engl J Med. 2008; 359 (15): 1543-54.
  • Rothnie KJ, Yan R, Smeeth L et al. Risk of myocardial infarction (MI) and death following MI in people with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. BMJ Open 2015; 5 (9): e007824.
  • López-Campos JL, Ruiz-Ramos M, Soriano JB. COPD mortality rates in Andalusia, Spain, 1975-2010: a joinpoint regression analysis. Int J Tuberc Lung Dis 2013; 17 (1): 131-6.
  • Chatila WM, Thomashow BM, Minai OA et al. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5 (4): 549-55.
  • Rothnie KJ, Yan R, Smeeth L et al. Risk of myocardial infarction (MI) and death following MI in people with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. BMJ Open 2015; 5 (9): e007824.
  • Cavaillès A, Brinchault-Rabin G, Dixmier A et al. Comorbidities of COPD. Eur Respir Rev 2013; 22 (130): 454-75.
  • Chen W, Thomas J, Sadatsafavi M et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med 2015; 3 (8): 631-9.
  • Maters GA, de Voogd JN, Sanderman R et al. Predictors of all-cause mortality in patients with stable COPD: medical co-morbid conditions or high depressive symptoms. COPD 2014; 11 (4): 468-74.
  • Cote C, Zilberberg MD, Mody SH et al. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J 2007; 29: 923-29.
  • Portillo K, Martinez-Rivera C, Ruiz-Manzano J. Anemia in chronic obstructive pulmonary disease. Does it really matter? Int J Clin Pract 2013; 67 (6): 558-65.
  • Maurer J, Rebbapragada V, Borson S et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest 2008 Oct; 134 (4 Suppl): 43S-56S.
  • de Voogd JN, Wempe JB, Koëter GH et al. Depressive symptoms as predictors of mortality in patients with COPD. Chest 2009; 135 (3): 619-25.
  • Papaioannou AI, Bartziokas K, Tsikrika S et al. The impact of depressive symptoms on recovery and outcome of hospitalised COPD exacerbations. Eur Respir J 2013; 41 (4): 815-23.
  • Papaioannou A, Bartziokas K, Tsikrika S et al. The impact of depressive symptoms on recovery and outcome of hospitalized COPD exacerbations. Eur Respir J 2013; 41: 815-823.
Fuente de los datos: Dialnet